Sudeep Pharma Ltd
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Sudeep Pharma Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
IPO Snapshot
Key metrics and details at a glance.
Price Band
₹593
Per ShareLot Size
25 Shares
Minimum Investment
₹14,825
Issue Size
₹895 Cr
Face Value
₹1
Per ShareIPO Type
Book Building
Retail Quota
35%
QIB Quota
50%
NII Quota
15%
IPO Timeline
Important dates for your applying strategy.
Subscription Status
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
Sudeep Pharma Ltd
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
89.37%
Promoter Holding (Post-Issue)
76.15%
Issue Type
Book Building
ISIN
INE0QPI01025
About the Company
We are a technology led manufacturer of excipients and specialty ingredients for the pharmaceutical, food and nutrition industries. We have established a presence in both, domestic and international markets, including key regions such as the United States, South America, Europe, the Middle East, Africa, and Asia-Pacific. We operate three manufacturing facilities in Vadodara, Gujarat as of June 30, 2025. Further, pursuant to our acquisition of NSS as a Material Subsidiary with effect from May 22, 2025, we also have a manufacturing facility in Ireland. For details in relation to expenses incurred by us on research and development.
Industry Overview
The global food ingredients market reflects distinct trends across regions, shaped by consumer preferences, regulatory environments, and industry advancements. The specialty food ingredients market is rapidly expanding, driven by growing consumer demand for healthier and more innovative food products. Advancements in distribution channels, personalized nutrition, and integration into functional foods contribute to the expansion of the global market for vitamins and minerals.
Company History
Our Company was incorporated as `Sudeep Pharma Private Limited' as a private limited company under the Companies Act, 1956 pursuant to a certificate of incorporation dated December 21, 1989, issued by the Registrar of Companies, Gujarat at Ahmedabad. Thereafter, our Company was converted into a public limited company and the name of our Company was accordingly changed to `Sudeep Pharma Limited' pursuant to fresh certificate of incorporation dated April 5, 1995, issued by the Assistant Registrar of Companies, Gujarat at Dadra & Nagar Haveli. Our Company was subsequently converted back to a private limited company under the Companies Act, 2013 vide a fresh certificate of incorporation dated October 1, 2014 issued by the Assistant Registrar of Companies, Gujarat at Ahmedabad, and the name of our Company was accordingly changed from `Sudeep Pharma Limited' to `Sudeep Pharma Private Limited'. Further, pursuant to the special resolution passed by our shareholders dated August 17, 2024 and the fresh certificate of incorporation dated October 21, 2024 issued by the Registrar of Companies, Central Processing Centre, our Company was converted into a public limited company and consequently, the name of our Company was changed to `Sudeep Pharma Limited'.
Products & Services
- The Company is a technology led manufacturer of excipients* and specialty ingredients for the pharmaceutical, food and nutrition industries.
Growth Strategy
- Expand into high-growth businesses.
- Expand market reach through multiple growth initiatives.
- Develop customized solutions and enter into strategic partnerships to drive growth.
- Integrate recently acquired entities and continue evaluating inorganic growth opportunities.
- Enhance manufacturing capabilities.
Customer Base
Wholesaler and Retailer
Financial Performance
Revenue, profit after tax and total assets across the last 3 reported financial years.
Revenue
Amount in ₹ crore
Profit After Tax (PAT)
Amount in ₹ crore
Total Assets
Amount in ₹ crore
Figures in ₹ crore, on a consolidated basis, as reported for FY24 to FY26.
Objects of the Issue
How the company plans to utilize IPO proceeds.
Use of Proceeds
The funds raised through this IPO will be used for:
Initial public offer of 15,092,749 equity shares of face value of Re.1/- each ("equity shares") of Sudeep Pharma Limited ("company") for cash at a price of Rs.593/- per equity share (including a share premium of Rs.592/- per equity share) ("offer price") aggregating to Rs.895.00 crores comprising a fresh issue of 1,602,023 equity shares of face value of Re.1/- aggregating to Rs. 95.00 crores by the company ("fresh issue") and an offer for sale of 13,490,726 equity shares of face value of Re.1/- aggregating to Rs.800.00 crores ("offered shares") by the selling shareholders, consisting of 3,567,670 equity shares of face value of Re.1/- aggregating to Rs.211.56 crores by SujitJjaysukh Bhayani, 8,418,856 equity shares of face value of Re.1/- aggregating to Rs. 499.24 crores by Sujeet Jaysukh Bhayani HUF, 750,000 equity shares of face value of Re.1/- aggregating to Rs.44.48 crores by Shanil Sujit Bhayani and 754,200 equity shares of face value of Re.1/- aggregating to Rs.44.72 crores by Avani Sujit Bhayani (collectively "the selling shareholders") and such equity shares offered by the selling shareholders ("offer for sale", and together with the fresh issue, the "offer"). Price Band: Rs. 593/- for equity share of face value of Rs. 1 each. The floor price is 593 times times the face value times of the face value of the equity shares. Bids can made for a minimum of 25 equity shares and in multiples of 25 equity shares thereafter.
*Subject to approvals and market conditions.
Strengths & Risks
Key competitive advantages and factors to consider before investing.
- Market leadership with a diversified product portfolio in a high barrier industry.
- Distinguished global customer base with long-standing relationships with key customers.
- Well-equipped and regulatory compliant Manufacturing Facilities.
- Strong research and development capabilities.
- Experienced Promoters and senior management team.
- The company generates a significant portion of its revenues from a limited number of customers and the loss of such customers or a decline in demand from such customers could adversely affect the company's business, results of operations, financial condition, and cash flows.
- The company generated 66.43%, 65.84%, 67.64% and 77.01% of its revenue from operations from the company's pharmaceutical, food and nutrition segment, in the three months ended June 30, 2025 and Fiscals 2025, 2024 and 2023, respectively. Any adverse developments affecting this segment may adversely affect its business, results of operations, financial condition, and cash flows.
- The company's Manufacturing Facilities are subject to periodic inspections and audits by regulatory authorities and customers and any manufacturing or quality control problems may subject us to regulatory action, damage its eputation and have an adverse effect on its business and results of operations.
- Three of the company's four Manufacturing Facilities and one of its two R&D facilities are concentrated in a single region and any adverse developments affecting this region could have an adverse effect on the company's business, results of operations, financial condition and cash flows.
- Any disruption, slowdown or shutdown in the company's manufacturing or R&D operations could adversely affect its business, results of operations, financial condition and cash flows.